EFX vs STRO
Equifax Inc (EFX) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Equifax Inc (EFX) is a consulting services company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported EFX revenue for 2024-12-31 was $5.68B. Net income was $607.3M. Revenue was up 7.9% from 2023-12-31 to 2024-12-31. EFX currently screens at market cap $33.00B and trailing P/E 54.0.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
EFX currently screens at market cap $33.00B and trailing P/E 54.0. STRO currently screens at market cap $470.8M.
Not investment advice. Open the EFX and STRO stock pages for the full models.
Not investment advice.